#CD30

[mementopath]

IHC pour tumeurs germinales

Frédérique Dijoud (CHU Lyon), plateforme nationale DES

[cosmeticbreastsurgeon]

Breast enlargement is a cosmetic procedure that enhances the size and shape of a woman's breasts, using either implants or fat transfer techniques. If you're considering breast enlargement in Leeds, there are many reputable clinics that can provide you with the safe and effective cosmetic surgery you need.

[doulayogimama]

I think I’m technically “late” today at CD30 but I’ve known I’m pregnant for 3 days now. The cheapie test picked it up clear as day on the first try which was CD 27.

My symptoms feel a lot more … advanced already than I remember feeling. My boobs feel so heavy, I’m slightly nauseous at some points in the day, and the sensations in my uterus sometimes are what I remember feeling a bit further into week 4.

What if it’s twins??? 😅

[kittykory]

Signing off #NiteFlirt for a while, but you can still buy my goodies at https://www.niteflirt.com/profile/Azn%20Boytoy?un=cd30#goodies.

[myrawjcsmicasereports]

Rapid progression of angioimmunoblastic t cell lymphoma after Covid-19 vaccination by Iryna Abramenko, MD in Journal of Clinical Case Reports Medical Images and Health Sciences

Abstract

We present the case of a 57-year-old male patient from Ukraine who developed tonsillitis and generalized lymphadenopathy approximately one week after receiving the first dose of the ChAdOx1 (AstraZeneca) anti-SARS-CoV-2 vaccine. A total body computerized tomography scan revealed pronounced lymphadenopathy above and below the diaphragm, and enlargement of the spleen. Histologic examination of the left inguinal lymph node revealed revealed lack of a clear separation of the cortical and paracortical areas. Expanded proliferation of vessels (postcapillary venules) around which atypical lymphoid cells of small and medium size were located. The most of atypical lymphoid cells expressed CD3, CD4, PD1, blc-6, and Ki-67 antigens, some cells also CD10-, CD30-positive. Diagnosis of angioimmunoblastic T-cell lymphoma (AITL), IVB Ann Arbor stage, was established. The patient received six courses of therapy CHOEP regimen. According to the results of treatment clinical and hematological remission is achieved. Thus, this article describes the second case of the development of AITL after vaccination. The accumulation of such data and their analysis will allow to make appropriate conclusions about the relationship of anti-SARS-CoV-2 vaccination with development of oncohematological diseases.

Introduction

SARS-Cov-2 virus infection is widespread throughout the world. By May 2023, the number of infected cases raised to 765,903,278 persons and a total 13,350,530,518 vaccine doses have been administered [1]. Vaccination is an effective mean of preventing infection and the development of severe forms of the disease. Eleven vaccines were recommended by World Health Organization for vaccination: Pfizer-BioNTech, Oxford-AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, CovoVax (Novavax formulation), Convidecia, Sanofi-GSK; a number of vaccines are under consideration [2]. Oxford-AstraZeneca, CoronaVac, Pfizer-BioNTech, and Moderna were used for vaccination against SARS-CoV-2 in Ukraine [3].

Vaccination leads to the development of protective antiviral immunity [4, 5]. In oncological patients, this may have ambivalent influence on tumor growth. Two cases of spontaneous tumor regression after SARS-Cov-2 vaccination have been described: shrinking of the cervical lymph node and resolution of the diffuse lung lesions in patient with a recurrent primary cutaneous anaplastic large-cell lymphoma one week after having received the first COVID-19 vaccination (BioNTech/Pfizer) [6]; and spontaneous regression of metastatic salivary gland myoepithelial carcinoma in patient one month after vaccination of mRNA-1273 COVID-19 (Moderna) vaccine [7]. Anti-cancer effect of COVID-19 vaccines (a decrease in tumor size, a decrease in the expression of tumor markers (VEGF, Ki-67, MMP-2/9), CD4/CD8 ratio, and metastasis to the vital organs) has been shown in 4T1 mice models [8].

On the other hand, cases of progression of oncohematological diseases after vaccination have also been described. Goldman et al. described rapid progression of angioimmunoblastic T cell lymphoma following BNT162b2 mRNA vaccine booster shot [9]. Cavanna et al. presented a case of anaplastic large-cell lymphoma that developed in a patient approximately 10 days after receiving the third dose of the BNT162b2 vaccine and summarized eight additional cases identified in the available literature [10]. There were four cases of diffuse large-B-cell lymphoma [11-13], one case of extranodal NK/T-cell lymphoma [12], one patient with subcutaneous panniculitis-like T-cell lymphoma [14], one case of marginal zone B-cell lymphoma [15] and one primary cutaneous anaplastic large-cell lymphoma  (developed at the SARS-CoV2 vaccine injection site) [16].

In this article, we report a case of angioimmunoblastic T-cell lymphoma developed shortly after SARS-CoV2 vaccination.

Case report

The patient is a 57-year-old Caucasian man with no previous history of disease. On May 6, 2021, he received the first dose of the ChAdOx1 (AstraZeneca). A few days later, he noted a flu-like syndrome and a sore throat. A diagnosis of tonsillitis was established. Antibacterial therapy was ineffective and within two weeks patient noted rapid increase of cervical, axillary, and inguinal lymph nodes. On May, 28, 2021, trephine biopsy of the left inguinal lymph node was performed.

Pathological examination revealed lack of a clear separation of the cortical and paracortical areas. Expanded proliferation of vessels (postcapillary venules) around which atypical lymphoid cells of small and medium size were located. Mitotic figures, single plasma cells, macrophages, neutrophils and eosinophils were present. The most of atypical lymphoid cells expressed CD3, CD4, PD1, blc-6, and Ki-67 antigens, some cells also CD10-, CD30-positive. Small clusters of CD20-positive cells were found between tumor cells. CD21- and CD23-positive follicular dendritic cells wrapped around postcapillary venules. Conclusion (8.06.2021): morphological changes in the lymph node and the immunophenotype of tumor cells correspond to diagnosis of angioimmunoblastic T cell lymphoma.

CT scan (29.05.2021) revealed pronounced lymphadenopathy above and below the diaphragm (diameters of cervical lymph nodes 10-24 mm, paratracheal lymph nodes 8-18 mm, bifurcation lymph nodes 14-25 mm, right axillary lymph nodes up to 20 mm, left axillary lymph nodes up to 15 mm, inguinal lymph nodes 8-28 mm), enlargement of the spleen (5.8x12.0x11.3 cm).

On June, 11, 2021 patient referred to the hematological department of National Research Center for Radiation Medicine. Complaints of the patient upon admission: fever (up to 380C) in the second half of the day, weakness, severe fatigue, enlargement of tonsils and lymph nodes. At examination: ECOG2 performance status. Weight 72 kg. Height 174 cm. Skin is pale. Peripheral lymph nodes are palpable: submaxillary up to 6 cm, cervical 4-6 cm, axillary up to 4 cm, inguinal up to 4 cm in diameter. The liver is not enlarged. The spleen is not palpable. Breathing is vesicular. Systolic murmur over the cardiac apex. The heart rhythm is correct. Blood pressure is 115/75 mm Hg, heart rate is 80 per min. There are no edema.

Bone marrow aspiration (11.06.2021) showed hypercellular marrow, dysplasia in erythropoiesis and megakariocytopoiesis, absence of blast cells, 5.6% of lymphocytes, no cytological signs of leukemic involvement. Among all nuclear bone marrow cells 1.68% with phenotype CD45dim+CD34+CD7+CD5+CD1a-TdT- were quantified by flow cytometry.

Except high level of blood lactate dehydrogenase (1249 units/L), and C-reactive protein (29.8 mg|L) other results of laboratory test of blood and urine were unremarkable.

Diagnosis of angioimmunoblastic T-cell lymphoma (AITL), IVB Ann Arbor stage, was established, and CHOEP (cyclophosphamide, vincristine, doxorubicin, etoposide and prednisone) regimen was initiated. The patient received six courses of therapy CHOEP regimen. According to the results of treatment clinical and hematological remission is achieved: hemodynamic parameters are stable, peripheral lymph nodes are not palpable, the spleen is not enlarged, and the size of the tonsils has decreased significantly.  At the time of this report the patient continues to be in clinical and hematological remission.

Discussion

The most exciting, intriguing question is: can vaccines induce the development of tumors, in particular, lymphoproliferative diseases?

So far, only the development of fibrosarcomas in cats after vaccination is known. This has been proven for killed adjuvanted virus vaccines (vaccination against rabies and feline leukemia virus). An inflammatory process with the formation of granulomatous nodules, only 5% of which subsequently undergo transformation, preceded tumor development. The interval between vaccine administration and detection of sarcoma varied from 4 months to several years [17]. In human, we found three similar cases in the literature: the development of lymphoma and undifferentiated, pleiomorphic high-grade sarcoma at the site of anti-SARS-CoV-2 vaccine administration [16, 18], and peripheral T-cell lymphoma at the injection site of influenza vaccination [19]. However, the interval between vaccine administration and tumor development was short, which does not fit into the classical scheme for the development of the oncological process (initiation, promotion, progression). Thus, it is unclear whether there is a true association between vaccination and the development of malignancy.

For the case described in this article, progression of preceding lymphoma under the influence of the vaccine seems more likely. Anti-SARS-CoV-2 vaccines cause a powerful immune response and stimulation of T- and B-lymphocytes, as well as the production of numerous cytokines [20]. Cases of post vaccine benign lymphadenopathy are described [21]. Today, AITL is recognized as a neoplasm derived from T-follicular helper cells [22, 23]. Up to 75% of AITL patients had a mutation RHOA G17V that facilitates proliferation and activation of several signaling pathways [24]. Since T-follicular helper cells are one of the main targets of mRNA vaccines [25], the Goldman et al. suggested that their stimulation under the influence of the vaccine can accelerate the development of AITL. In their case the malignant cells of patient had a mutation RHOA G17V that could make them especially sensitive to anti-SARS-CoV-2 vaccines [9]. Unfortunately, molecular genetic studies have not been performed in our patient.

Thus, this article describes the second case of the development of AITL after vaccination. The accumulation of such data and their analysis will allow to make appropriate conclusions about the relationship of anti-SARS-CoV-2 vaccination with development of oncohematological diseases. It will contribute to our better understanding of the possible negative consequences of anti-SARS-CoV-2 vaccination and their prevention as well.

[moleculardepot]

Human CD30 Ligand (CD30L)

Human CD30 Ligand (CD30L) Catalog number: B2018504 Lot number: Batch Dependent Expiration Date: Batch dependent Amount: 1 µg Molecular Weight or Concentration: ~19 kDa Supplied as: Powder Applications: a molecular tool for various biochemical applications Storage: −20°C Keywords: CD30L Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water…

[ptmasterguide]

Brentuximab vedotin (Working)

Brentuximab vedotin (Working) Brentuximab vedotin is a targeted therapy used to treat Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). It’s an antibody-drug conjugate (ADC) that combines an antibody that targets CD30, a protein found on the surface of cancer cells, with a potent anti-cancer drug called vedotin. Working: Target recognition: The antibody component of brentuximab vedotin…

[credenceresearchdotblog]

The demand for antibody drug conjugate was valued at USD 9984.20 million in 2023 and is expected to reach USD 26594.21 million in 2032, growing at a CAGR of 11.50% between 2024 and 2032.The Antibody-Drug Conjugate (ADC) market represents a groundbreaking intersection of biotechnology and pharmacology, offering a novel approach to cancer treatment. ADCs are sophisticated biopharmaceuticals designed to deliver cytotoxic drugs directly to cancer cells, minimizing damage to healthy tissues. This targeted therapy approach has gained substantial attention in recent years due to its potential to enhance the efficacy and safety profiles of cancer treatments. As the ADC market continues to expand, it is poised to revolutionize oncology and drive significant advancements in personalized medicine.

Browse the full report at https://www.credenceresearch.com/report/antibody-drug-conjugate-market

Market Overview

The global ADC market has witnessed rapid growth, driven by increasing cancer prevalence, technological advancements in drug development, and rising demand for targeted therapies. According to recent market research, the ADC market was valued at approximately USD 4.8 billion in 2022 and is expected to reach over USD 12 billion by 2028, growing at a compound annual growth rate (CAGR) of 16.7% during the forecast period.

This growth is fueled by the rising incidence of cancer worldwide, coupled with the limitations of conventional cancer therapies, such as chemotherapy and radiation, which often result in severe side effects. ADCs, by contrast, offer a more precise mechanism of action, delivering cytotoxic agents directly to cancer cells while sparing healthy tissues. This specificity reduces adverse effects and improves patient outcomes, making ADCs a promising option in the oncology landscape.

Technological Advancements

Advancements in ADC technology have been pivotal in driving market growth. Early-generation ADCs faced challenges such as low therapeutic indices, off-target toxicities, and limited efficacy. However, recent innovations have addressed these issues, leading to the development of more stable linkers, improved antibody engineering, and the use of highly potent cytotoxic agents.

Modern ADCs utilize cleavable linkers that release the drug payload only in the presence of specific enzymes or conditions within the cancer cell, ensuring targeted drug delivery. Additionally, advancements in monoclonal antibody engineering have enhanced the ability of ADCs to bind selectively to tumor-specific antigens, further improving their therapeutic potential.

Key Market Players

Several pharmaceutical companies are at the forefront of the ADC market, investing heavily in research and development to bring new ADCs to market. Notable players include:

1. Seagen Inc.: Known for its pioneering work in ADCs, Seagen’s ADC technology has led to the successful development of drugs like Adcetris, used in the treatment of Hodgkin lymphoma and other CD30-expressing lymphomas.

2. Roche: A global leader in oncology, Roche has developed Kadcyla, an ADC used in the treatment of HER2-positive breast cancer. Kadcyla combines the HER2-targeting properties of trastuzumab with a cytotoxic agent, offering a targeted approach to treating this aggressive form of breast cancer.

3. AstraZeneca: With the development of Enhertu, an ADC for HER2-positive breast cancer, AstraZeneca has further solidified its position in the ADC market. Enhertu’s unique design allows it to deliver a higher drug-to-antibody ratio, enhancing its therapeutic efficacy.

Challenges and Opportunities

Despite the promising outlook, the ADC market faces several challenges. The complexity of ADC development, high production costs, and stringent regulatory requirements can hinder market growth. Additionally, issues related to drug resistance and the need for personalized approaches to treatment pose ongoing challenges.

However, these challenges also present opportunities for innovation. Companies are exploring new ADC technologies, such as bispecific ADCs that target multiple antigens, and the use of alternative payloads to overcome drug resistance. Furthermore, ongoing research into biomarker-driven patient selection is expected to enhance the precision of ADC therapies, aligning them with the principles of personalized medicine.

Future Outlook

The future of the ADC market looks promising, with continued advancements in technology and a growing pipeline of ADC candidates in clinical trials. As more ADCs receive regulatory approval and enter the market, the adoption of this targeted therapy is expected to increase, offering new hope to cancer patients worldwide.

Moreover, the expanding application of ADCs beyond oncology, such as in the treatment of autoimmune diseases, presents additional growth opportunities. As research in this area progresses, ADCs may become a cornerstone of targeted therapy across various therapeutic areas.

Key Players

Seagen Inc.

Takeda Pharmaceutical Company Ltd.

AstraZeneca Plc.

F. Hoffmann-La Roche Ltd.

Pfizer Inc.

ImmunoGen Inc.

Gilead Sciences Inc.

Daiichi Sankyo Company Ltd.

Segmentation

By Product

Kadcyla

Enhertu

Adcetris

Padcev

Trodelvy

Polivy

Others

By Disease Type

Breast Cancer

Blood Cancer

Others

By Linker Type

Non-Cleavable

Cleavable

By Target

HER2

CD22

CD30

Others

By Payload Type

MMAE/Auristatin

Calicheamicin

Maytansinoids

Others

By Region

North America

The U.S

Canada

Mexico

Europe

Germany

France

The U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/antibody-drug-conjugate-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[marketblogresearch]

CAR-T Therapy Market Share, Growth, Sales, Trends, Supply, Forecast 2030

The “CAR-T Therapy Market Share, Size, and Trends | 2030” is market research by The Insight Partners. The CAR-T Therapy market has perceived tides of change in the recent past. This study offers precise projections after detailed scrutiny of a range of factors impacting the business.  Considering the present market scenario, this report brings forward correct predictions on revenue, market size, and CAGR of the CAR-T Therapy market. The novel market research which is based on a fact-based foundation is now accessible for purchase. This report can make a variance in wide decision-making and drive business forward in the right direction.

Business is no longer a game of instincts when it comes to capitalizing on new production lines. In a highly competitive CAR-T Therapy market, companies may face several challenges. Having trusted market research is always endorsed for both veteran and new entrants. CAR-T Therapy Market report presents a thorough analysis of local, regional, and global market scenarios through the following details.

Report Attributes

Details

Segmental Coverage

By Targeted Antigen

CD 19

BCMA

HER2

GD2

CD 20

CD22

CD30

CD33

HER1

Therapeutic Application

Acute Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Diffuse Large B-Cell Lymphoma

Follicular Lymphoma

Geography

North America

Europe

Asia Pacific

and South and Central America

Regional and Country Coverage

North America (US, Canada, Mexico)

Europe (UK, Germany, France, Russia, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, Australia, Rest of APAC)

South / South & Central America (Brazil, Argentina, Rest of South/South & Central America)

Middle East & Africa (South Africa, Saudi Arabia, UAE, Rest of MEA)

Market Leaders and Key Company Profiles

Novartis International AG

Kite Pharma, Inc. (Gilead Sciences, Inc.)

Juno Therapeutics (Celgene Corporation)

Bluebird Bio, Inc. (Celgene Corporation)

Sorrento Therapeutics Inc.

Mustang Bio, Inc

Aurora Biopharma Inc.

Legend Biotech (Genscript Biotech Corporation)

Pfizer, Inc.

CARsgen Therapeutics, Ltd.

Other key companies 

Competitive Landscape

Knowing the state of rivals is a strategically right move to outperform them. This report is the right place to explore key strategies, developments, and recent launches by key CAR-T Therapy market players. This report emphasizes an analysis of business strategies and expected growth opportunities for brands.

Key Coverings:

Current and Future Market Estimates- CAR-T Therapy Market Share, CAGR, and Forecast | 2030

Market Dynamics – Drivers, Challenges, Regional Trends, and Market Opportunities

Market Segmentation – Product, Application, End-use Industries, and Regional Growth Prospects.

Competition Matrix – Key Market Players and Strategies

Recent Developments and Innovation Contributing Market Growth

Need a Customized Market Research Report?

You can always share any specific requirements that you have, and our team will adjust the scope of research offerings as per your needs.

The following are some customizations our clients frequently ask for:

The CAR-T Therapy market report can be customized based on specific regions/countries as per the intention of the business

The report production was facilitated as per the need and following the expected time frame

Insights and chapters tailored as per your requirements.

Depending on the preferences we may also accommodate changes in the current scope.

Key Questions Addressed in the CAR-T Therapy Market Research Include:

What are present CAR-T Therapy market values, and what can be expected in the upcoming decade?

What are the key segments in the CAR-T Therapy market?

What is the regional distribution of the CAR-T Therapy market report?

What are the key players and their recent strategies?

What are the key factors driving CAR-T Therapy market growth?

What are regulatory concerns and requirements businesses have to compel?

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us: www.theinsightpartners.com

[sophiareddy123]

The Global Antibody-drug Conjugates Market is Segmented by Product Type (Adcetris, Kadcyla, and Other Product Types), Application (Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Other Applications), Technology (Cleavable Linker and Non-cleavable Linker), Target Type (CD30 Antibodies, HER2 Antibodies, and Other Target Types), End User (Hospitals and Specialty Cancer Centers, Biotechnology and Pharmaceutical Companies, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America).

Download Free Sample Report - Antibody-drug Conjugates Market

[monica-bing1920]

Unlocking Hope: The Uses of Adcetris (Brentuximab Vedotin) in Cancer Treatment

Cancer, a formidable adversary, has witnessed significant advancements in its treatment in recent years. Among the innovative therapies that have emerged, Adcetris, a medication containing Brentuximab Vedotin, has demonstrated remarkable promise in the fight against certain types of cancer. In this article, we will explore the uses and significance of Adcetris in cancer treatment.

Understanding Adcetris:

Adcetris is a groundbreaking drug that falls under the category of antibody-drug conjugates (ADCs). It combines a monoclonal antibody with a potent chemotherapy drug. The monoclonal antibody specifically targets cancer cells, guiding the chemotherapy drug directly to its target, minimizing damage to healthy cells, and enhancing treatment efficacy.

Key Uses of Adcetris:

1. Hodgkin Lymphoma (HL): Adcetris has proven to be a game-changer in the treatment of Hodgkin lymphoma, particularly in cases where the cancer has relapsed (returned) or failed to respond to other treatments. It is often used in combination with chemotherapy or as a standalone therapy.

2. Systemic Anaplastic Large Cell Lymphoma (sALCL): Adcetris is also indicated for the treatment of systemic anaplastic large cell lymphoma, an aggressive type of non-Hodgkin lymphoma. It has shown effectiveness in patients who have not responded well to previous treatments.

3. Cutaneous T-Cell Lymphoma (CTCL): In some cases of cutaneous T-cell lymphoma, a type of skin lymphoma, Adcetris has been used to manage the disease, particularly when other treatments have not provided adequate results.

How Adcetris Works:

Adcetris works through a multi-step process:

1. Targeting Cancer Cells: The monoclonal antibody component of Adcetris is designed to bind specifically to a protein called CD30, which is found on the surface of some cancer cells, including Hodgkin lymphoma cells and systemic anaplastic large cell lymphoma cells.

2. Delivering Chemotherapy: Once the antibody attaches to the cancer cell, Adcetris is internalized by the cell. Inside the cell, it releases its chemotherapy payload, which is a potent drug called monomethyl auristatin E (MMAE).

3. Cell Death: MMAE disrupts the cancer cell's microtubules, preventing cell division and ultimately leading to cell death.

Benefits and Considerations:

Adcetris has offered new hope to patients with Hodgkin lymphoma, sALCL, and CTCL, especially those who have exhausted other treatment options. It has been associated with high response rates and durable remissions in many cases.

However, like all medications, Adcetris is not without potential side effects. These can include nausea, fatigue, peripheral neuropathy, and lowered blood cell counts, among others. Patients considering Adcetris should discuss potential side effects and benefits with their healthcare team.

Conclusion:

Adcetris, containing Brentuximab Vedotin, is a significant advancement in the field of cancer treatment. Its targeted approach to delivering chemotherapy directly to cancer cells has transformed the prognosis for patients with certain types of lymphomas. While it is not a cure, Adcetris has provided renewed hope and extended the lives of many individuals facing the challenges of cancer. As research continues and medical science evolves, it is likely that Adcetris will play an even more pivotal role in the fight against cancer in the years to come. To know more: https://www.gnhindia.com/products/adcetris-50mg/

[mementopath]

IHC Synonymes HL

ALK1 : hématologie

ALK2 / ALK5A4 : poumon (théranostique), certains diagnostiques

BRG1 : SMARCA4

CD15 : LeuM1

CD20 : L26

CD30 : BerH2

CD99 : O13

EBER : SHS

HER2 : CerB2

ICOS : CD278

INI1 : SMARCA1, BAF47

MelanA : A103

[ramkumarss]

Antibody Drug Conjugates Market Size, Share | Growth drivers 2023

According to Precision Business Insights, the global Antibody Drug Conjugates Market is poised to grow at a significant CAGR of 12.6% during forecast period 2023-29

The global antibody drug conjugates market size was valued at USD 6.84 billion in 2022 and is poised to grow at a significant CAGR of 12.6% during the forecast period 2023-29. It also includes market size and projection estimations for each of the five major regions from 2023 to 2029. The research report includes historical data, trending features, and market growth estimates for the future. Furthermore, the study includes a global and regional estimation and further split by nations and categories within each region. The research also includes factors and barriers to the antibody drug conjugates market growth, as well as their impact on the market's future growth. The report gives a comprehensive overview of both primary and secondary data.  

View the detailed report description here - https://www.precisionbusinessinsights.com/market-reports/antibody-drug-conjugates-market              

The global antibody drug conjugates market segmentation: 1) By Drugs : Kadcyla, Adcertis

2) By Mechanism Of Action : CD30 Antibodies, HER2 Antibodies

3) By Application : Breast Cancer, Lymphoma

The primary factors of the antibody drug conjugates market drivers are the increasing incidences of cancer. The antibody drug conjugates market report helps to provide the best results for business enhancement and business growth. It further helps to obtain the reactions of consumers to a novel product or service. It becomes possible for business players to take action for changing perceptions. It uncovers and identifies potential issues of the customers. It becomes easy to obtain the reactions of the customers to a novel product or service. It also enlightens further advancement, so it suits its intended market.

The antibody drug conjugates market researchreport gives a comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America was the largest region in the antibody drug conjugates market report, accounting for the highest share in 2022. It was followed by Asia Pacific, and then the other regions. Request sample report at - https://www.precisionbusinessinsights.com/request-sample/?product_id=23717                The important profiles and strategies adopted by antibody drug conjugates market key players Roche Holding AG (Switzerland) Pfizer Inc. (U.S.) Bayer HealthCare (Germany) Progenics Pharmaceuticals (U.S.) Roche Holding AG (Switzerland) ImmunoGen, Inc. (U.S.) Celldex Therapeutics (U.S.) AbbVie Inc. (U.S.) Millennium Pharmaceuticals (U.S.) Agensys, Inc. (U.S.), covered here to help them in strengthening their place in the market.

About Precision Business Insights: We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

Contact:

Mr. Satya

Precision Business Insights | Toll Free: +1 866 598 1553

Email: sales@precisionbusinessinsights.com Kemp House, 152 – 160 City Road, London EC1V 2NX Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

[robbialy]

A day in a haematopathomorphologist’s life: the R-S Cell! • Reed–Sternberg cells are distinctive, giant cells found with light microscopy in biopsies from individuals with Hodgkin lymphoma. They are usually derived from B lymphocytes, classically considered crippled germinal center B cells. In the vast majority of cases, the immunoglobulin genes of Reed-Sternberg cells have undergone both V(D)J recombination and somatic hypermutation, establishing an origin from a germinal center or postgerminal center B cell. Despite having the genetic signature of a B cell, the Reed-Sternberg cells of classical Hodgkin lymphoma fail to express most B-cell–specific genes, including the immunoglobulin genes. The cause of this wholesale reprogramming of gene expression has yet to be fully explained. It presumably is the result of widespread epigenetic changes of uncertain etiology, but is partly a consequence of so-called “crippling” mutations acquired during somatic hypermutation. Seen against a sea of B cells, they give the tissue a moth-eaten appearance. Reed–Sternberg cells are large (30–50 microns) and are either multinucleated or have a bilobed nucleus with prominent eosinophilic inclusion-like nucleoli (thus resembling an "owl's eye" appearance). Reed–Sternberg cells are CD30 and CD15 positive, usually negative for CD20 and CD45. The presence of these cells is necessary in the diagnosis of Hodgkin lymphoma – the absence of Reed–Sternberg cells has very high negative predictive value. The presence of these cells is confirmed mainly by use of biomarkers in immunohistochemistry. https://www.instagram.com/p/Cp3Id5WslWUTmt-Agf3DyAeJ-e59eLxKTMcpjs0/?igshid=NGJjMDIxMWI=

[petnews2day]

Copper Dog runs the Keweenaw | News, Sports, Jobs

New Post has been published on https://petn.ws/XZsm7

Copper Dog runs the Keweenaw | News, Sports, Jobs

Katelyn Dehlin (bib 41) of Basalt Tamaskan Kennel in Negaunee, Mich. preps her eager team in the starting chute of the CD30 Friday night. The howls of huskies resounded off sandstone facades in downtown Calumet Friday as the 14th annual CopperDog150 race took off towards Eagle Harbor. The start of the […]

See full article at https://petn.ws/XZsm7 #DogNews #CopperDogRunsTheKeweenaw, #CopperDogRunsTheKeweenawLocalNews, #CopperDogRunsTheKeweenawNews, #CopperDogRunsTheKeweenawOutdoors, #FrontPage